Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Total Debt (2016 - 2025)

Avalo Therapeutics filings provide 11 years of Total Debt readings, the most recent being $370000.0 for Q2 2025.

  • On a quarterly basis, Total Debt changed N/A to $370000.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $370000.0, a N/A change, with the full-year FY2024 number at $360000.0, changed N/A from a year prior.
  • Total Debt hit $370000.0 in Q2 2025 for Avalo Therapeutics, up from $360000.0 in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $32.8 million in Q4 2021 to a low of $360000.0 in Q4 2024.
  • Median Total Debt over the past 5 years was $12.0 million (2022), compared with a mean of $11.6 million.
  • The widest YoY moves for Total Debt: up 58.93% in 2022, down 58.93% in 2022.
  • Avalo Therapeutics' Total Debt stood at $32.8 million in 2021, then plummeted by 58.93% to $13.5 million in 2022, then dropped by 22.36% to $10.5 million in 2023, then crashed by 96.56% to $360000.0 in 2024, then grew by 2.78% to $370000.0 in 2025.
  • The last three reported values for Total Debt were $370000.0 (Q2 2025), $360000.0 (Q1 2025), and $360000.0 (Q4 2024) per Business Quant data.